Friday, October 19, 2018
IBB 113.00 1.69 (1.47%)XBI 87.54 1.76 (1.97%)
Ticker Current Price Change Graph
IBB 113.00 1.69 (1.47%)
XBI 87.54 1.76 (1.97%)
Last updated: ago
Sign in to Endpoints
Menu Search Chat
  • Special Reports
  • Deep Dives
  • ENDPOINTS 100
  • News
  • Protocols
  • Bioregnum
  • Endpoints Careers
  • About
  • Advertise
  • Privacy Policy
  • Reader center

FDA offers a proposal to help generic drug developers get simultaneous approvals in multiple markets

by Zachary Brennan - RAPSenvelope — on October 19, 2018 01:43 AM EDT

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

by John Carrollenvelope — on October 18, 2018 10:00 AM EDT

Biotech vets launch a neuro startup with $54.5M to kickstart R&D

by John Carrollenvelope — on October 18, 2018 09:30 AM EDT
Updated: 10:36 AM

Amgen sharpens focus on genetic sequencing with $66M investment

by Endpoints Staffenvelope — on October 18, 2018 09:05 AM EDT
Updated: 10:31 AM

AbbVie frontloads Morphic fibrosis development deal with $100M in cash

by John Carrollenvelope — on October 18, 2018 07:59 AM EDT

FDA slaps down Novartis’ blockbuster pitch for canakinumab — so what went wrong?

by John Carrollenvelope — on October 18, 2018 05:46 AM EDT
Updated: 06:59 AM

FDA slaps a full hold on Affimed’s T cell engager in wake of a lethal reaction

by John Carrollenvelope — on October 18, 2018 04:47 AM EDT

Giant Pfizer looking to shed close to 2,000 jobs as it crafts a ‘simpler’ management structure

by John Carrollenvelope — on October 18, 2018 04:32 AM EDT

From zero to hero: Endocyte’s little deal a year ago spurred a comeback capped by $2.1B Novartis buyout

by John Carrollenvelope — on October 18, 2018 03:15 AM EDT
Updated: 03:29 AM

UPDATED: J&J takes a $630M asset hit on the books, shuttering PhIIb trials as its $1.75B RSV drug teeters on the brink

by John Carrollenvelope — on October 17, 2018 11:06 AM EDT
Updated: 11:27 AM

  • 1
  • 2
  • 3
  • 393

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
  • Endpoints Careers
  • About Endpoints
  • Privacy Policy
  • Advertise

copyright 2018 Endpoints Company

Yes, I'd like to subscribe No, thanks
I'm already a subscriber
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
Sure No
← Go back

Sign in to Endpoints News

I forgot my password Request a magic link
← Go back

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.
Please note the Magic link is one-time use only and valid for only 24 hours.
← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.
Please note this link is one-time use only and valid for only 24 hours.